Pilot Study Of Novel Combination Of Maraviroc + Atazanavir/Ritonavir vs. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Naive HIV-Infected Patients With R5 HIV-1.

Trial Profile

Pilot Study Of Novel Combination Of Maraviroc + Atazanavir/Ritonavir vs. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Naive HIV-Infected Patients With R5 HIV-1.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2013

At a glance

  • Drugs Maraviroc (Primary) ; Atazanavir/ritonavir; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jan 2013 Primary endpoint 'Virological-response' has been met.
    • 27 Jul 2012 Results presented at the 19th International AIDS Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top